The Lawyer’s new China Elite report contains the most detailed research available on the PRC legal market and contains unparalleled insight into the country's leading law firms. They vary in size, practice focus and geographic coverage, but they all share one common quality – ambition... Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
Dechert partner Diane Sullivan has scored a major victory for Merck & Co in the ongoing battle over rheumatoid arthritis drug Vioxx.
On 3 November, a New Jersey jury threw out the claims of an Idaho man who claimed that Vioxx was responsible for a heart attack he suffered in 2001. Dechert teamed up with New York firm Hughes Hubbard & Reed to represent Merck.
Meanwhile, it has emerged that an Eversheds team, headed by partner Kiko Carrión, is acting for Merck in Spain, where litigation over Vioxx is also threatened.
The New Jersey case is the second piece of Vioxx litigation to reach a verdict, following the August decision of a Texas jury to award $253m (£144.9m) in damages against Merck. That jury found Vioxx to have been responsible for causing cardiovascular damage, and ultimately death, to a patient.
The decision kick-started a wave of litigation across the world, with a number of UK firms becoming involved in filing claims on both sides of the Atlantic. Cases are also expected in European countries, including Germany.